Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series
{{output}}
Mepolizumab, which selectively suppresses IL-5, has been proven to be effective in treating eosinophilic granulomatosis with polyangiitis. However, the medium-to long-term outcomes of mepolizumab initiation in the early remission induction phase remain unclear... ...
